focus -WSS

focus

author：entertainment 2025-08-28 06:24:00 - browse：23191

After months of vigorous deliberations, I’m thrilled to announce our 2023 STATUS List — the definitive roster of leaders in health, medicine, and the life sciences whose work over the past year has advanced those fields.

There were, of course, many contenders to choose from. For this second annual list, we’ve selected just 46 — an homage to the number of chromosomes in human DNA. Many are well-known as changemakers; others are largely unheralded heroes. They are CEOs, philanthropists, government officials, and health advocates. All have compelling stories to tell.

Our editorial team painstakingly researched and identified hundreds of finalists. In winnowing down the list, judges placed special emphasis on people who have sought to help others and build community in these often-divisive times. One note: Our news coverage is independent of this list, and we remain committed to tough-minded reporting on the people and institutions shaping life sciences.

While I have your attention, I want to point you to some of our most talked-about exclusive stories in recent days: A new STAT investigation exposes how Medicare Advantage plans use algorithms to cut off care for seniors in need, and we took a closer look at how a Medicare Advantage business is strangling one of its first funders. We’re aggressively reporting on the consequences for biotech of the Silicon Valley Bank collapse.

And over the coming months, in our series “The Obesity Revolution,” we’ll explore a class of obesity drugs that is transforming patients’ lives, dividing medical experts, and spurring one of the biggest business battles in years.

For full access to our exclusive reporting, please consider purchasing a STAT+ subscription. Get 15% off an annual subscription by using promo code STAT15 when you check out.

As always, please reach out to me with feedback. I’m at [email protected].

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Trump surgeon general acknowledges mistakes during Covid

WSS

Ionis drug prevents swelling attacks due to hereditary angioedema

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

House transparency, PBM reform bill gains bipartisan support

Snackable artificial intelligence, expert AI, and the pharma industry

Amazon on where the company's health care bets are headed next

focus

focus

focus

Apple is now the first public company to be valued at $3 trillion

Kaiser's Risant Health gobbled up Geisinger. Who is next?

How to save PrEP access — and even expand it

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Malaria cases in Florida and Texas: Here’s what you need to know

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

As demand for Covid shots wanes, Moderna seeks its next success

HIV drugs protect against transmission, even in unprotected sex

In age of alternative facts, a scholarly course on calling out crap

Ultragenyx gene therapy for rare liver ailment succeeds in late

Wikipedia

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Ethical issues complicate the benefits of medical crowdfunding

Snackable artificial intelligence, expert AI, and the pharma industry

ALS advocates say criticism of new drugs misses bigger picture

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

knowledge

entertainment

knowledge

entertainment